IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

Business Wire • Aug 8, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Aug 7, 2026

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.

The Motley Fool • Aug 3, 2026

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

Zacks Investment Research • Jul 30, 2026

Ionis Pharmaceuticals Q2 Earnings Call Highlights

Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia.

MarketBeat • Jul 29, 2026

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 29, 2026

Ionis reports second quarter 2026 financial results and highlights progress on key programs

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026. “With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our ot.

Business Wire • Jul 29, 2026

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to earnings of $0.86 per share a year ago.

Zacks Investment Research • Jul 29, 2026

Compared to Estimates, Ionis Pharmaceuticals (IONS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Jul 29, 2026

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.“As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Frank's profound contributions include pioneering the use of antisense medicines in neurological.

Business Wire • Jul 29, 2026